Avalon GloboCare Corp. Files 8-K
Ticker: ALBT · Form: 8-K · Filed: Dec 19, 2024 · CIK: 1630212
Sentiment: neutral
Topics: filing, sec, listing
Related Tickers: ALBT
TL;DR
ALBT's 8-K filed 12/13/24 confirms Nasdaq listing, no major news yet.
AI Summary
On December 13, 2024, Avalon GloboCare Corp. (ALBT) filed an 8-K report. The filing indicates that the company's common stock is traded on The Nasdaq Capital Market under the ticker symbol ALBT. No specific transactions or significant events are detailed in the provided excerpt of the filing.
Why It Matters
This filing confirms the trading status of Avalon GloboCare Corp.'s common stock on the Nasdaq Capital Market, which is important for investors tracking the company's public market presence.
Risk Assessment
Risk Level: low — The provided excerpt is a standard 8-K filing cover page and does not contain information about significant financial events, operational changes, or legal matters that would indicate a higher risk level.
Key Players & Entities
- Avalon GloboCare Corp. (company) — Registrant
- ALBT (company) — Trading Symbol
- The Nasdaq Capital Market (company) — Exchange
- December 13, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report current information about Avalon GloboCare Corp. as required by the SEC, with the earliest reported event date being December 13, 2024.
On which exchange is Avalon GloboCare Corp.'s common stock traded?
Avalon GloboCare Corp.'s common stock is traded on The Nasdaq Capital Market.
What is the trading symbol for Avalon GloboCare Corp. common stock?
The trading symbol for Avalon GloboCare Corp. common stock is ALBT.
What is the state of incorporation for Avalon GloboCare Corp.?
Avalon GloboCare Corp. is incorporated in Delaware.
What is the principal executive office address for Avalon GloboCare Corp.?
The principal executive offices of Avalon GloboCare Corp. are located at 4400 Route 9 South, Suite 3100, Freehold, NJ 07728.
Filing Stats: 1,373 words · 5 min read · ~5 pages · Grade level 12.5 · Accepted 2024-12-19 16:30:31
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ALBT The Nasdaq Capital M
- $2,845,000.00 — missory note in the principal amount of $2,845,000.00 (the "Note") to Mast Hill Fund, L.P., a
- $150,000 — Note, the Company paid a waiver fee of $150,000 to Holder, and the Company issued to Ho
- $1,000 — C Preferred Stock has a stated value of $1,000 (the "Stated Value"). The Series C Pre
- $2 — es") at a conversion per share equal to $2.41, at the option of the holder, at any
Filing Documents
- ea0225230-8k_avalon.htm (8-K) — 35KB
- ea022523001ex10-1_avalon.htm (EX-10.1) — 15KB
- ea022523001ex10-2_avalon.htm (EX-10.2) — 112KB
- ea022523001ex10-3_avalon.htm (EX-10.3) — 11KB
- ex10-3_001.jpg (GRAPHIC) — 949KB
- ex10-3_002.jpg (GRAPHIC) — 1072KB
- ex10-3_003.jpg (GRAPHIC) — 1290KB
- ex10-3_004.jpg (GRAPHIC) — 1537KB
- ex10-3_005.jpg (GRAPHIC) — 1722KB
- ex10-3_006.jpg (GRAPHIC) — 1910KB
- ex10-3_007.jpg (GRAPHIC) — 1913KB
- ex10-3_008.jpg (GRAPHIC) — 1581KB
- ex10-3_009.jpg (GRAPHIC) — 1556KB
- ex10-3_010.jpg (GRAPHIC) — 137KB
- ex10-3_011.jpg (GRAPHIC) — 172KB
- ex10-3_012.jpg (GRAPHIC) — 540KB
- 0001213900-24-110582.txt ( ) — 20184KB
- albt-20241213.xsd (EX-101.SCH) — 3KB
- albt-20241213_lab.xml (EX-101.LAB) — 33KB
- albt-20241213_pre.xml (EX-101.PRE) — 22KB
- ea0225230-8k_avalon_htm.xml (XML) — 4KB
02. Unregistered
Item 3.02. Unregistered Sales of Equity Securities. The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. The securities described above have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or the securities laws of any state, and were offered and sold in reliance on the exemption from registration under the Securities Act afforded by Section 4(a)(2) thereof. Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On December 13, 2024, the Company filed a certificate of designations of preferences, rights, and limitations of Series C Convertible Preferred Stock (the "Series C Certificate of Designations") with the Department of State, Division of Corporations, of the State of Delaware, which provides for the designation of 10,000 shares of Series C Preferred Stock of the Company, par value $0.0001 per share, upon the terms and conditions as set forth in the Series C Certificate of Designations. Each share of Series C Preferred Stock has a stated value of $1,000 (the "Stated Value"). The Series C Preferred Stock shall rank (i) senior to the Company's common stock (the "Common Stock") and any other class or series of capital stock of the Company created hereafter, the terms of which specifically provide that such class or series shall rank junior to the Series C Preferred Stock, (ii) pari passu with any class or series of capital stock of the Company created hereafter specifically ranking, by its terms, on par with the Series C Preferred Stock, (iii) pari passu with Series B Convertible Preferred Stock of the Company (the "Series B Preferred Stock") with respect to its rights, preferences and restrictions, and (iv) subordinate to the Series A Convertible Preferred Stock of the Company (the "Series A Preferred Stock"). Holders of the Series C Preferred Stock shall be entitled to receive, and the Company shall pay, dividends on shares of
01. Financial
Item 9.01. Financial (d) Exhibits Exhibit No. Description 10.1 Consent, Acknowledgement, and Waiver Agreement, between the Company and Holder, dated as of December 15, 2024 10.2 Common Stock Purchase Warrant, between the Company and Holder, dated as of December 15, 2024. 10.3 Certificate of Designations of Preferences and Rights of Series C Convertible Preferred Stock of the Company, as filed on December 13, 2024, with the Department of State, Division of Corporations, of the State of Delaware. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVALON GLOBOCARE CORP. Dated: December 19, 2024 By: /s/ Luisa Ingargiola Name: Luisa Ingargiola Title: Chief Financial Officer 3